Drug intelligence / Profile preview

nomacopan + oral corticosteroids

Development stage
Unknown
Lead developer
Akari Therapeutics
Modality
Recombinant Proteins and Enzymes, Small Molecules
Administration
Subcutaneous, Oral
01

Overview

Nomacopan + oral corticosteroids is a combination regimen involving **nomacopan**, a recombinant protein that selectively inhibits both complement component C5 and leukotriene B4 (LTB4), and **oral corticosteroids**, a class of synthetic glucocorticoid drugs that act as immunosuppressants. Nomacopan works by binding and neutralizing C5, preventing its cleavage to the potent inflammatory mediator C5a and the membrane attack complex component C5b, as well as directly neutralizing LTB4, a chemoattractant for neutrophils. Oral corticosteroids modulate gene expression to suppress broad proinflammatory pathways. The combination is studied for autoimmune inflammatory diseases, particularly **bullous pemphigoid**, to suppress disease activity via inhibition of complement-driven and leukotriene-driven inflammation, as well as general immunosuppression from corticosteroids.

02

Targets

GR (Glucocorticoid receptor)C5

Beyond the preview

Go deeper on nomacopan + oral corticosteroids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nomacopan + oral corticosteroids.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call